Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...

Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill.

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Viking Therapeutics (NASDAQ:VKTX) fell ~43% as analysts reacted to mid-stage trial data for its oral GLP-1/GIP dual receptor agonist VK2735, a potential rival to Eli Lilly’s (NYSE:LLY) orforglipron ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

Viking Therapeutics' stock was crushed after a mid-stage trial of its oral weight-loss drug. Viking Therapeutics Inc. on Tuesday announced that a trial showed its oral weight-loss drug works - and ...

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

A doctor has explained how the body adjusts to the weight-loss drug Mounjaro during its first month of use. Weight loss drugs ...

(CNN) - Patients in the United States can now get the popular diabetes and weight loss drug Ozempic for half the price. Novo ...

With Trump's backing, the pharma industry is leaning into the idea of more "direct-to-consumer" sales. But experts say the ...